Myofascial pain syndrome in a patient with ankylosing spondylitis: experience with tolperisone


DOI: https://dx.doi.org/10.18565/pharmateca.2022.13.151-156

A.A. Klimenko, N.A. Demidova, D.Yu. Andriyashkina, A.A. Kondrashov, D.V. Somov, A.V. Novikova

Department of Faculty Therapy n.a. Academician A.I. Nesterov, Faculty of General Medicine, of the Pirogov Russian National Research Medical University, Moscow, Russia
Background. Myofascial pain syndrome (MPS) is the most common pathology in the structure of musculoskeletal pain and accounts for 85–90%. The development of MPS is associated with overstrain and microtraumatization of the muscles, followed by the development of the inflammatory process, the release of excess acetylcholine, which promotes muscle contraction. In addition, hyperplasia of con- nective tissue fibers occurs, the number of nociceptors in muscle fascia increases, local blood flow is disturbed, which ultimately leads to ischemia of muscle tissue areas, increased muscle tone, shortening of muscle fibers, and pain syndrome.
Description of the clinical case. The article presents a clinical case illustrating the effectiveness of an integrated approach in the treatment of a patient with MPS. The clinical manifestations of MPS, approaches to diagnosis and methods of treatment are discussed. Conclusion. The possibilities of muscle relaxants (tolperisone) in correcting muscle spasm and reducing pain in myofascial syndrome have been demonstrated.

About the Autors


Corresponding author: Natalya A. Demidova, Cand. Sci. (Med.), Associate Professor at the Department of Faculty Therapy n.a. acad. A.I. Nesterov, Faculty of General Medicine, Pirogov Russian National Research Medical University, Moscow, Russia; ndemidova03@gmail.com, ORCID: https://orcid.org/0000- 0001-6890-8777; elibrary SPIN: 1168-1967


Similar Articles


Бионика Медиа